Skip to main content

marlotamig

Generic: Marlotamig

marlotamig: 4 clinical trials tracked.

marlotamig evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about marlotamig, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 1 study sponsors
Clinical Trials (4)

Combining Capecitabine/Oxaliplatin Chemotherapy With Cemiplimab Alone or in Combination With Fianlimab or REGN7075 for the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

NCT07281768·Phase 2
Recruiting

Primary endpoint: Pathologic complete response (pCR) rate

InterventionalRandomizedopen66 targetStarted 2026-07Completion 2030-071 site · United StatesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07154290·Phase 2·REGN
Recruiting

Primary endpoint: Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

InterventionalRandomizedopen300 targetStarted 2026-03Completion 2030-0615 sites · United StatesRegeneron Pharmaceuticals

A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients With Resectable Non-Small Cell Lung Cancer

NCT06465329·Phase 2·REGN
Active, not recruiting

Primary endpoint: Major pathologic response (MPR) rate as determined by central blinded independent pathology review (BIPR)

InterventionalRandomizedopen120 targetStarted 2024-11Completion 2030-0547 sites · Brazil, France, Germany, Spain…Regeneron Pharmaceuticals

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT04626635·Phase 1/Phase 2·REGN
Active, not recruiting

Primary endpoint: The incidence of Dose-Limiting Toxicities (DLTs) during the DLT period

Interventionalopen548 targetStarted 2020-12Completion 2027-0350 sites · France, Israel, Netherlands, Poland…Regeneron Pharmaceuticals